Clinical Trial Update: Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002) [Phase 1]

View source ↗

Summary

Phase 1 single-dose safety and pharmacokinetics study of MK-4250 monotherapy in ART-naive HIV-1 infected participants; completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• MK-4250

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 Infection | Phase 1 | Status: COMPLETED | Results posted: 2019-10-30